Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics Inc (FATE)
:FATE
Total Valuation
Fate Therapeutics has a market cap or net worth of $119.19M. The enterprise value is ―.
Market Cap$119.19M
Enterprise Value―
Share Statistics
Fate Therapeutics has 114,603,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding114,603,910
Owned by Insiders18.11%
Owned by Institutions0.30%
Financial Efficiency
Fate Therapeutics’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -51.34%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-51.34%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee75.31K
Profits Per Employee-1.03M
Employee Count181
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fate Therapeutics is -1.01. Fate Therapeutics’s PEG ratio is ―.
PE Ratio-1.01
PS Ratio0.00
PB Ratio0.31
Price to Fair Value0.59
Price to FCF-0.79
Price to Operating Cash Flow-0.80
PEG Ratio―
Income Statement
In the last 12 months, Fate Therapeutics had revenue of 13.63M and earned -186.26M in profits. Earnings per share was -1.64.
Revenue13.63M
Gross Profit13.63M
Operating Income-210.28M
Pretax Income-186.26M
Net Income-186.26M
EBITDA-176.58M
Earnings Per Share (EPS)-1.64
Cash Flow
In the last 12 months, operating cash flow was -122.87M and capital expenditures -730.00K, giving a free cash flow of -123.60M billion.
Operating Cash Flow-122.87M
Free Cash Flow-123.60M
Free Cash Flow per Share-1.08
Dividends & Yields
Fate Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.99
52-Week Price Change-74.94%
50-Day Moving Average1.01
200-Day Moving Average2.26
Relative Strength Index (RSI)46.70
Average Volume (3m)2.27M
Important Dates
Fate Therapeutics upcoming earnings date is Jul 30, 2025, TBA Not Confirmed.
Last Earnings DateApr 30, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend Date―
Financial Position
Fate Therapeutics as a current ratio of 7.58, with Debt / Equity ratio of 26.75%
Current Ratio7.58
Quick Ratio7.58
Debt to Market Cap0.45
Net Debt to EBITDA-0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fate Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fate Therapeutics EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.92.
EV to Sales17.37
EV to EBITDA-1.34
EV to Free Cash Flow-1.92
EV to Operating Cash Flow-1.93
Balance Sheet
Fate Therapeutics has $279.07M in cash and marketable securities with $85.27M in debt, giving a net cash position of -$193.80M billion.
Cash & Marketable Securities$279.07M
Total Debt$85.27M
Net Cash-$193.80M
Net Cash Per Share-$1.69
Tangible Book Value Per Share$2.80
Margins
Gross margin is -189.23%, with operating margin of -1542.63%, and net profit margin of -1366.46%.
Gross Margin-189.23%
Operating Margin-1542.63%
Pretax Margin-1366.46%
Net Profit Margin-1366.46%
EBITDA Margin-1295.41%
EBIT Margin-1434.52%
Analyst Forecast
The average price target for Fate Therapeutics is $6.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.17
Price Target Upside493.27% Upside
Analyst ConsensusModerate Buy
Analyst Count12
Revenue Growth Forecast-78.55%
EPS Growth Forecast-0.92%